News Moderna’s Capabilities Beyond Covid-19 Vaccines are Underappreciated UBS analyst Eliana Merle has upgraded shares of biotech company Moderna to Buy from Neutral, attributing the move to investors’ lack of appreciation ... By Artur FernandoJune 30, 20230
BlackRock is reviewing TechBerry and negotiating a possible full or partial acquisition of the company June 20, 2024
